| Revista: | Annals of hepatology |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000407474 |
| ISSN: | 1665-2681 |
| Autores: | Forns, Xavier1 Samuel, Didier2 Mutimer, David3 Fagiuoli, Stefano4 Navasa, Miquel1 Agarwal, Kosh5 Berenguer, Marina6 Colombo, Massimo7 Herzer, Kerstin8 Nevens, Frederik9 Daems, Bjorn10 Janssen, Katrien10 Ouwerkerk Mahadevan, Sivi10 Kimko, Holly11 Lathouwers, Erkki10 Witek, James11 Solingen Ristea, Rodica Van11 |
| Instituciones: | 1Universidad de Barcelona, Barcelona. España 2Universite Paris-Sud, París. Francia 3Queen Elizabeth's Hospital, Birmingham. Reino Unido 4Ospedale Papa Giovanni XXIII, Bergamo, Lombardia. Italia 5NHS Foundation Trust, King's College Hospital, Londres. Reino Unido 6Hospital Universitario La Fe, Valencia. España 7Universita degli Studi di Milano, Ospedale Maggiore Policlinico, Milán, Lombardia. Italia 8University of Duisburg-Essen, University Hospital, Essen, Nordrhein-Westfalen. Alemania 9Universite Catholique de Louvain, Lovaina. Bélgica 10Janssen Global Services, Beerse, Antwerpen. Bélgica 11Janssen Global Services, Trenton, Nueva Jersey. Estados Unidos de América |
| Año: | 2016 |
| Periodo: | Jul-Ago |
| Volumen: | 15 |
| Número: | 4 |
| Paginación: | 512-523 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Analítico, descriptivo |
| Resumen en inglés | REPLACE study (NCT01571583) investigated telaprevir-based triple therapy in patients who have recurrent genotype 1 hepatitis C virus (HCV) infection following liver transplantation and are on a stable immunosuppressant regimen of tacrolimus or cyclosporin A. Patients received telaprevir 750 mg 8-hourly with pegylated interferon 180 μg weekly and ribavirin 600 mg daily, followed by a further 36 weeks of pegylated interferon and ribavirin alone and 24 weeks of follow-up. Efficacy (sustained virological response [SVR] 12 weeks after last planned study dose), safety and tolerability of telaprevir throughout the study were assessed. Pharmacokinetics of telaprevir, tacrolimus and cyclosporin A were also examined. Results. Results. In Results. total, 74 patients were recruited. Overall, 72% (53/74; 95% CI: 59.9 to 81.5) of patients achieved SVR at 12 weeks following completion of treatment. Anticipated increases in plasma concentrations of tacrolimus and cyclosporin A occurred during telaprevir treatment and were successfully managed through immunosuppressant dose reduction and, for tacrolimus, reduced dosing frequency. Safety and tolerability of telaprevir-based triple therapy were generally comparable with previous data in non-transplant patients, although rates of reported anemia (55% [41/74]) were higher. Elevated plasma creatinine (46% [34/74]) was observed during REPLACE – consistent with the post-liver transplant population and the co-administered immunosuppressants. Conclusion. Conclusion. Telaprevir-based triple therapy in patients with recurrent genotype 1 HCV infection following liver transplantation produced high rates of SVR. Therapeutic concentrations of immunosuppressants were maintained successfully through dose modification during telaprevir treatment |
| Disciplinas: | Medicina |
| Palabras clave: | Farmacología, Gastroenterología, Hepatitis C, Trasplante de hígado, Inmunosupresión |
| Keyword: | Medicine, Gastroenterology, Pharmacology, Hepatitis C, Liver transplantation, Immunosuppression |
| Texto completo: | Texto completo (Ver PDF) |
